Tesamorelin and Ipamorelin Research

Laboratory studies on Tesamorelin and Ipamorelin highlight their distinct yet complementary mechanisms in stimulating growth hormone (GH) pathways. Each peptide promotes GH release through unique receptor interactions, and their combined effects may extend beyond GH elevation alone.

Research demonstrates their individual impacts on visceral fat reduction, muscle preservation, gastrointestinal function, and bone metabolism.

Effects on Growth Hormone Release

Tesamorelin: A growth hormone-releasing hormone (GHRH) analog, it enhances basal and pulsatile GH secretion and significantly elevates insulin-like growth factor-1 (IGF-1) levels. In a study with healthy subjects, Tesamorelin increased mean overnight GH, average log(10) GH peak area, and basal GH secretion (Stanley et al., 2011).

Ipamorelin: A pentapeptide that mimics ghrelin and binds to the ghrelin receptor (GHSR) in the brain, selectively stimulating GH release from the pituitary gland, thereby increasing plasma GH levels. Its selectivity for GH release is comparable to GHRH (Raun et al., 1998).

Lipolysis

Tesamorelin: Effective in reducing visceral adipose tissue (VAT) in HIV patients with lipodystrophy, it decreases VAT, hepatic fat, and trunk-to-appendicular fat ratio while improving liver enzymes (Spooner & Olin, 2012; Fourman et al., 2017).

Ipamorelin: Stimulates appetite and enhances gastric motility, accelerating gastrointestinal transit. In a rodent model, repetitive dosing increased fecal pellet output, food intake, and body weight gain, suggesting potential benefits for postoperative ileus (Venkova et al., 2009).

Muscle Growth

Tesamorelin: Increases skeletal muscle area and density, particularly in the rectus and psoas muscles, among individuals with significant VAT reduction (Adrian et al., 2018).
Ipamorelin: In an adult rat model, it counteracted glucocorticoid-induced muscle catabolism, increasing maximum tetanic tension in calf muscles when co-administered with glucocorticoids (Andersen et al., 2001).

Bone Density

Ipamorelin: Increases bone mineral content (BMC) in young adult female rats, primarily due to increased cross-sectional bone area in cortical bone, though total BMC corrected for body weight and cortical volumetric BMD remained unchanged (Svensson et al., 2000).

References

1. Stanley, T. L., et al. (2011). *The Journal of Clinical Endocrinology and Metabolism*, 96(1), 150–158. https://doi.org/10.1210/jc.2010-1587
2. Raun, K., et al. (1998). *European Journal of Endocrinology*, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
3. Spooner, L. M., & Olin, J. L. (2012). *Annals of Pharmacotherapy*. https://doi.org/10.1345/aph.1Q629
4. Fourman, L. T., et al. (2017). *AIDS*, 31, 2253–2259.
5. Venkova, K., et al. (2009). *Journal of Pharmacology and Experimental Therapeutics*, 329, 1110–1116. https://doi.org/10.1124/jpet.108.149211
6. Adrian, S., et al. (2018). *The Journal of Frailty & Aging*, 8, 154–159. https://doi.org/10.14283/jfa.2018.45
7. Andersen, N. B., et al. (2001). *Growth Hormone & IGF Research*, 11(5), 266–272. https://doi.org/10.1054/ghir.2001.0239
8. Svensson, J., et al. (2000). *The Journal of Endocrinology*, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569

Storage instructions:

Our products are manufactured using lyophilization, a freeze-drying process that ensures 100% stability for shipping and storage for up to 3-4 months at room temperature. Lyophilization involves freezing the peptides and applying low pressure to sublimate water directly from solid to gas, resulting in a stable, crystalline white powder known as lyophilized peptide.

Once reconstituted with bacteriostatic water, peptides must be refrigerated at under 4°C (39°F) to maintain stability, remaining effective for up to 60 days before noticeable degradation occurs. For immediate use within days, weeks, or a few months, refrigeration is sufficient, as lyophilized peptides are typically stable at room temperature for several weeks.

For long-term storage (several months to years), freezing at temperatures as low as -80°C (-112°F) is recommended to preserve peptide stability. Always store peptides away from light and keep them cold upon receipt to ensure optimal quality.

General Tips

• Store in a cold, dry, dark environment.
• Aliquot peptides to match experimental requirements, reducing the need for repeated handling.
• Avoid light exposure to prevent photodegradation.
• Minimize air exposure to reduce oxidation risks.
• Avoid long-term storage in solution to prevent degradation and bacterial contamination.

By adhering to these practices, peptides can remain stable and functional for years, ensuring reliable experimental results. If you need specific guidance on a particular peptide sequence or storage setup, feel free to contact us for more details!